Ezra E.W. Cohen, MD, of the University of California, San Diego, discusses study findings on chemotherapy plus cetuximab in combination with motolimod immunotherapy in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. (Abstract LBA37)
Judith Balmaña, MD, PhD, of Vall d’Hebron University Hospital, discusses in Spanish the findings of a single-agent phase II trial on the antitumor activity of lurbinectedin in BRCA1/2-associated metastatic breast cancer patients. (Abstract 223O)
Sian A. Pugh, MBBS, of Southampton University Hospital, discusses 6 to 12-year findings on the scheduled use of the CEA tumor marker and CT follow-up to detect recurrence of colorectal cancer. (Abstract 453O)
Shou-Ching Tang, MD, PhD, of the Georgia Cancer Center, discusses findings on a novel peptide–paclitaxel conjugate that crosses the blood-brain barrier and shows activity in breast cancer patients with recurrent central nervous system metastases. (Abstract 324O)
Martin Reck, MD, PhD, of the LungenClinic, discusses in German study findings on pembrolizumab vs platinum-based chemotherapy as first-line therapy for advanced non-small cell lung cancer with a PD-L1 tumor proportion score ≥50%. (Abstract LBA8)
Alain Ravaud, MD, PhD, of Bordeaux University Hospital, discusses phase III findings on sunitinib vs placebo as adjuvant treatment for high-risk renal cell carcinoma after nephrectomy. (Abstract LBA11)
